Építés alatt – nem éles oldal
Belépés
LeállítvaNo phase

NOLA (NeuWave Observational Liver Ablation) Registry

Megadott ok: Change in Company Strategy

Key facts

Where
Charlottesville, Houston, Jacksonville, Loma Linda, Los Angeles, Madison, New York, Philadelphia, Sacramento, Sarasota, Seattle és Sylmar, Egyesült ÁllamokSee the 14 sites

Where in Egyesült Államok

  • University of VirginiaCharlottesville, Egyesült ÁllamokNo longer taking part
  • MD Anderson Cancer CenterHouston, Egyesült ÁllamokNo longer taking part
  • Mayo ClinicJacksonville, Egyesült ÁllamokNo longer taking part
  • Loma Linda University Medical CenterLoma Linda, Egyesült ÁllamokNo longer taking part
  • Cedars-Sinai Medical CenterLos Angeles, Egyesült ÁllamokNo longer taking part
  • David Geffen School of Medicine at UCLALos Angeles, Egyesült ÁllamokNo longer taking part
  • University of Wisconsin at MadisonMadison, Egyesült ÁllamokNo longer taking part
  • Icahn School of Medicine at Mount SinaiNew York, Egyesült ÁllamokNo longer taking part
  • Memorial Sloan-Kettering Cancer CenterNew York, Egyesült ÁllamokNo longer taking part
  • Thomas Jefferson UniversityPhiladelphia, Egyesült ÁllamokNo longer taking part
  • Sutter Institute for Medical ResearchSacramento, Egyesült ÁllamokNo longer taking part
  • Sarasota Memorial HospitalSarasota, Egyesült ÁllamokNo longer taking part
  • University of Washington Medical CenterSeattle, Egyesült ÁllamokNo longer taking part
  • Olive View UCLASylmar, Egyesült ÁllamokNo longer taking part

Trial details

Who runs it
Ethicon, Inc.
Trial code
NCT04107766
Record updated
2026. április 17.
Original description
This is a multicenter, observational registry that follows patients for a total of 5 years from the date of the first liver ablation procedure with the NEUWAVE Microwave Ablation System.Read full original descriptionShow less

A Multicenter Observational Registry to Develop Ablation Parameter Guidance for Microwave Liver Ablation of Soft Tissue Lesions

This is a multicenter, observational registry that follows patients for a total of 5 years from the date of the first liver ablation procedure with the NEUWAVE Microwave Ablation System.

Inclusion: Patients who underwent or are scheduled to undergo a microwave ablation of one or more liver lesions with the NEUWAVE Microwave Ablation System per the device's Instructions for Use (IFU); Patients with signed informed consent (or waiver approved by IRB/EC) who are willing to comply with the assessment schedule, and willing to have data included in the database; Patients greater than or equal to 22 years old at the time of informed consent (or waiver approved by IRB/EC).

Exclusion: Patient is currently participating, or planning to participate, in another NeuWave/Ethicon-funded clinical trial or registry studying microwave ablation in the liver. Note: roll-over patients from previous NeuWave trials are permitted; Patients with a life expectancy of less than 1 year, in the opinion of the treating physician; Use of microwave ablation purely as a transection tool, rather than focused liver lesion ablation.

ClinicalTrials.gov NCT04107766